Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IDE397

Phase 1Small molecule

IIDEAYA Biosciences

1

Indications

3

Total Trials

3

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLC AdenocarcinomaRecruiting

NSCLC AdenocarcinomaPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Solid Tumors

NCT04794699

Q2 2028

Phase 1Recruiting

NSCLC Adenocarcinoma

NCT07277413

Clinical

Trials by Indication[1]

Solid Tumors2 trials

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting·IIDEAYA Biosciences·Phase 1·NCT04794699·180 enrolled

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Active, not recruiting· Amgen logo

Amgen·Phase 1/2·NCT05975073·53 enrolled

NSCLC Adenocarcinoma1 trial

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Recruiting·IIDEAYA Biosciences·Phase 1·NCT07277413·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IDE397. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IDE397 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IDE397. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IDEAYA Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIDEAYA Biosciences

Related News